Topoisomerase I poisons-induced autophagy: Cytoprotective, Cytotoxic or Non-protective

References

• Patel NH. The Roles of Autophagy and Senescence in the Tumor Cell Response to Radiation. Radiat Res, 2020;194(2):103–115.
   PubMed Web of Science ®Google Scholar
• Xu J, Gewirtz DA. Is Autophagy Always a Barrier to Cisplatin Therapy? Biomolecules. 2022;12(3).
   Google Scholar
• Xu J, Elshazly AM, Gewirtz DA. The Cytoprotective, Cytotoxic and Nonprotective Functional Forms of Autophagy Induced by Microtubule Poisons in Tumor Cells—Implications for Autophagy Modulation as a Therapeutic Strategy. Biomedicines. 2022;10(7).
   Web of Science ®Google Scholar
• Finnegan RM. Therapeutic Potential for Targeting Autophagy in ER+ Breast Cancer. Cancers (Basel). 2022;14(17).
   Web of Science ®Google Scholar
• Sebastián D, Zorzano A Self-Eating for Muscle Fitness: Autophagy in the Control of Energy Metabolism. Developmental Cell. 2020;54(2):268–281.
   Web of Science ®Google Scholar
• Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. The Journal of pathology. 2010;221(1):3–12.
   PubMed Web of Science ®Google Scholar
• Parzych KR, Klionsky DJ. An overview of autophagy: morphology, mechanism, and regulation. Antioxidants & redox signaling. 2014;20(3):460–473.
   PubMed Web of Science ®Google Scholar
• Patel NH. Chapter One - Autophagy and senescence in cancer therapy, in Advances in Cancer Research. In Gewirtz DA, Fisher PB, editors. Academic Press; 2021. p. 1–74.
   Google Scholar
• Coly PM. The Autophagy Machinery: A New Player in Chemotactic Cell Migration. 2017;11.
   Google Scholar
• Sui X. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013;4(10):e838.
   PubMed Web of Science ®Google Scholar
• Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27–42.
   PubMed Web of Science ®Google Scholar
• Gewirtz DA. The four faces of autophagy: implications for cancer therapy. Cancer Res. 2014;74(3):647–51.
   PubMed Web of Science ®Google Scholar
• Sharma K. Cytotoxic autophagy in cancer therapy. International journal of molecular sciences. 2014;15(6):10034–10051.
   PubMed Web of Science ®Google Scholar
• Wilson EN. A switch between cytoprotective and cytotoxic autophagy in the radiosensitization of breast tumor cells by chloroquine and vitamin D. 2011;2(5):272–285.
   Google Scholar
• Bristol ML. Dual functions of autophagy in the response of breast tumor cells to radiation: cytoprotective autophagy with radiation alone and cytotoxic autophagy in radiosensitization by vitamin D3. 2012;8(5)739–753.
   Google Scholar
• Dou Q. Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer. Cancer Res. 2016;76(15):4457–69.
   PubMed Web of Science ®Google Scholar
• Circu M. Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells. PLoS One. 2017;12(9):e0184922.
   PubMed Web of Science ®Google Scholar
• Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. British Journal of Cancer. 2012;106(1):18–24.
   PubMed Web of Science ®Google Scholar
• Robert J, Rivory L. Pharmacology of irinotecan. Drugs Today (Barc). 1998;34(9):777–803.
   Web of Science ®Google Scholar
• Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chemical reviews. 2009;109(7):2894–2902.
   PubMed Web of Science ®Google Scholar
• Delgado JL. Topoisomerases as anticancer targets. The Biochemical journal. 2018;475(2):373–398.
   PubMedGoogle Scholar
• Jonsson E. Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines. Eur J Cancer. 2000; 36(16):2120–7.
   PubMed Web of Science ®Google Scholar
• de Man FM. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet. 2018;57(10):1229–1254.
   PubMed Web of Science ®Google Scholar
• Abang AM. The clinical pharmacology of topoisomerase I inhibitors. Semin Hematol. 1998;35(3 Suppl 4):13–21.
   Web of Science ®Google Scholar
• Kawato Y. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51(16):4187–91.
   PubMed Web of Science ®Google Scholar
• Di Paolo A. Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. Curr Clin Pharmacol. 2006;1(3):311–23.
   Google Scholar
• Glassman DC. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC Cancer. 2018;18(1):693.
   PubMedGoogle Scholar
• Thomas A, Pommier Y. Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019;25(22):6581–6589.
   PubMed Web of Science ®Google Scholar
• Morise M. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer. Jpn J Clin Oncol. 2014;44(9):846–51.
   PubMed Web of Science ®Google Scholar
• Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene. 2003;22(47):7296–7304.
   PubMed Web of Science ®Google Scholar
• Feeney GP. Tracking the cell cycle origins for escape from topotecan action by breast cancer cells. Br J Cancer. 2003;88(8):1310–7.
   Web of Science ®Google Scholar
• Elshazly AM, Gewirtz DA. An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer. Cancer Drug Resist. 2022;5(2):472–486.
   Google Scholar
• Kanzawa F. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 1990;50(18):5919–24.
   PubMed Web of Science ®Google Scholar
• Takahashi T. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. Jpn J Cancer Res. 1997;88(12):1211–7.
   Google Scholar
• Chiu YH. Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy. Int J Oncol. 201853(5):1967–1979.
   PubMed Web of Science ®Google Scholar
• Zhu Q. Irinotecan Induces Autophagy-Dependent Apoptosis and Positively Regulates ROS-Related JNK- and P38-MAPK Pathways in Gastric Cancer Cells. Onco Targets Ther. 2020;13:2807–2817.
   PubMed Web of Science ®Google Scholar
• Chen JH. ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells. Autophagy. 2015;11(2):239–52.
   PubMed Web of Science ®Google Scholar
• Sinha BK. Synergistic enhancement of topotecan-induced cell death by ascorbic acid in human breast MCF-7 tumor cells. Free Radic Biol Med. 2017;113:406–412.
   Web of Science ®Google Scholar
• Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015;125(1):25–32.
   PubMed Web of Science ®Google Scholar
• Chen P, CQ synergistically sensitizes human colorectal cancer cells to SN-38/CPT-11 through lysosomal and mitochondrial apoptotic pathway via p53-ROS cross-talk. Free Radic Biol Med. 2017;104:280–297.
   PubMed Web of Science ®Google Scholar
• Chen MC. Resistance to irinotecan (CPT-11) activates epidermal growth factor receptor/nuclear factor kappa B and increases cellular metastasis and autophagy in LoVo colon cancer cells. Cancer Lett. 2014;349(1):51–60.
   Web of Science ®Google Scholar
• Tamura N. Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines. Anticancer Res. 2012;32(11):4823–32.
   Web of Science ®Google Scholar
• Zhang S. Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy. Chinese medicine. 2022;17:55.
   Google Scholar
• Paillas S. MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy. Autophagy. 2012;8(7):1098–112.
   PubMed Web of Science ®Google Scholar
• Wang Y. Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells. Chin J Cancer. 2011;30(10):690–700.
   Google Scholar
• Tasdemir E. A dual role of p53 in the control of autophagy. Autophagy. 2008;4(6):810–4.
   PubMed Web of Science ®Google Scholar
• Tasdemir E. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol. 2008;10(6):676–87.
   PubMed Web of Science ®Google Scholar
• Mrakovcic M, Fröhlich LF. p53-Mediated Molecular Control of Autophagy in Tumor Cells. Biomolecules. 2018;8(2).
   Web of Science ®Google Scholar
• Bykov VJN. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18(2):89–102.
   PubMed Web of Science ®Google Scholar
• Tomicic MT, Christmann M, Kaina B. Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. Cancer Res. 2005;65(19):8920–6.
   Web of Science ®Google Scholar
• Li DD. The inhibition of autophagy sensitises colon cancer cells with wild-type p53 but not mutant p53 to topotecan treatment. PLoS One. 2012;7(9):e45058.
   Web of Science ®Google Scholar
• Gewirtz DA. An autophagic switch in the response of tumor cells to radiation and chemotherapy. Biochem Pharmacol. 2014;90(3):208–11.
   PubMed Web of Science ®Google Scholar
• Amin A. Defective autophagosome formation in p53-null colorectal cancer reinforces crocin-induced apoptosis. Int J Mol Sci. 2015;16(1):1544–61.
   Web of Science ®Google Scholar
• Patel NH. Influence of nonprotective autophagy and the autophagic switch on sensitivity to cisplatin in non-small cell lung cancer cells. Biochem Pharmacol. 2020;175:113896.
   Web of Science ®Google Scholar
• Li Y, Chen Y. AMPK and Autophagy. Adv Exp Med Biol. 2019;1206:85–108.
   PubMed Web of Science ®Google Scholar
• Fielden J, M Popović, K Ramadan. TEX264 at the intersection of autophagy and DNA repair. Autophagy. 2022;18(1):40–49.
   PubMed Web of Science ®Google Scholar
• Fielden J. TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts. Nature Communications. 2020;11(1):1274.
   Web of Science ®Google Scholar
• Elshazly A M, VI V Nguyen T, Gewirtz D A. Is autophagy induction by PARP inhibitors a target for therapeutic benefit? Oncology Research. 2022;30(1):1–12.
   Web of Science ®Google Scholar